Bevacizumab and erlotinib in the treatment of patients (pts) with metastatic carcinoma of unknown primary site: A Sarah Cannon Research Institute phase II trial

3088 Background: Bevacizumab (B) has anti-tumor activity in several advanced epithelial neoplasms including colorectal and renal. Erlotinib (E) has activity in lung and head/neck carcinomas. We pre...